Merits of a new drug trial for ALS? [4] (multiple letters)

Science

Volumn 308, Issue 5722, 2005, Pages 632-633

  Beghi, Ettore ^a   Bendotti, Caterina ^a   Mennini, Tiziana ^a   Miller, Tim ^b   Cleveland, Don ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; GLUTAMIC ACID;

DRUG DEVELOPMENT;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PUBLICATION; TREATMENT OUTCOME;

AMINO ACID TRANSPORT SYSTEM X-AG; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CEFTRIAXONE; CLINICAL TRIALS; GLUTAMIC ACID; HUMANS; RATS; SPINAL CORD;

EID: 17844396477     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (0)